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Abstract
Purpose The purpose of this study was to describe the
visual prognosis as well as the frequency and clinical sever-
ity of central nervous system involvement in all acute pos-
terior multifocal placoid pigment epitheliopathy (APMPPE)
patients of one centre.
Methods A retrospective database review of all patients and
a prospective clinical, ophthalmological and neurological
follow-up, if possible, were conducted.
Results Eighteen patients with APMPPE were included
with a mean follow-up of 17.1 months. Thirteen patients
participated in a follow-up exam. Visual acuity improved in
9 of 18 patients to a mean of 0.17 log minimum angle of
resolution (MAR) in the worse eye and remained stable in
eight patients (mean, 0.03 logMAR). In the majority of
patients, the 30° static perimetry improved at follow-up
compared to the initial exams. Still, in up to 50 to 60 %,
small visual field defects persisted. Overall, 11 patients
(61 %) showed neurologic symptoms of varying severity.
The most common neurological symptom was headache in
nine (50 %) patients. Other symptoms included paraesthesias,
psychosis, vertigo, and, as the most severe complication,
stroke due to cerebral vasculitis. Fifteen patients were treated
with systemic corticosteroids.
Conclusions Visual prognosis is good in patients with
APMPPE, but visual field defects may remain. Neurological
signs and symptoms, especially headaches, are frequent in
APMPPE and should be taken seriously. Adequate inves-
tigations including MRI and CSF examination should be
initiated in these patients.
Keywords APMPPE . Ocular outcome . Neurological
complications . Cerebral vasculitis
Introduction
Acute posterior multifocal placoid pigment epitheliopathy
(APMPPE) is a rare inflammatory eye disease that affects
the choriocapillaris, retinal pigment epithelium and outer
retina of otherwise healthy young adults. It was first de-
scribed by Gass in 1968 [1]. Patients present with sudden
painless visual loss in one or typically both eyes. Fundus-
copically creamy white lesions can be seen (Fig. 1a, b)
which later can leave chorioretinal scars. In the fluorescein
angiogram, the lesions typically show early hypofluorescence
and late hyperfluorescence (“blocks early, stains late”, Fig. 1c,
d). The full extent of the affected choroid can be seen using
indocyanine green as a dye; where the lesions lead to early and
late hypofluorescence. Flu-like symptoms often precede the
onset of the disease, therefore a viral etiology has been dis-
cussed. Several authors described central nervous system
(CNS) involvement ranging in severity from headaches to
diffuse cerebral vasculitis leading to stroke and death [2].
Overall visual prognosis in APMPPE has been described as
good, but there are patients that experience incomplete visual
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recovery [3]. The purpose of this study is to describe the visual
prognosis as well as the frequency and clinical severity of
CNS involvement in all APMPPE patients of one centre.
Methods
A retrospective database review of all APMPPE patients of
one centre between 2003 and February 2010 was performed.
All patients were asked to participate in a prospective clinical,
ophthalmological and neurological follow-up. For the follow-
up exam, ophthalmological tests included visual acuity, Ams-
ler test, multifocal electroretinogram (mfERG, RETIscan, Ro-
land Consult), 30° visual field (Octopus 900 or Octopus 101,
Haag-Streit International), fundus autofluorescence (FAF)
(Heidelberg Retina Angiograph II, Heidelberg Engineering),
funduscopy and fundus photography (Zeiss Camera). A fluo-
rescein or indocyanine green angiogram was only performed
when clinically indicated (Heidelberg Retina Tomograph II,
Heidelberg Engineering). Neurologic tests included a general
neurological examination, magnetic resonance imaging
(MRI) of the brain, transcranial and carotid duplex (TCD)
sonography, electroencephalogram, somatosensory evoked
potentials, visual evoked potentials and examination of cere-
brospinal fluid (CSF) if clinically indicated. All tests were
voluntary for the participants, and refusal of single tests did
not lead to exclusion from the study. The study was approved
by the ethics committee of the University of Heidelberg.
Patients signed a patient consent form.
Results
Eighteen patients with APMPPE were identified in our
database and were included in the study. Thirteen patients
(72 %) participated in a follow-up exam; five did not agree
to come or could not be contacted. In all patients, there was
no doubt that the correct diagnosis was APMPPE. All 18
patients had bilateral involvement. Nine patients were fe-
male and nine were male. The mean age at time of diagnosis
was 28.61 years (17–58 years). The mean follow-up time
was 17.12 months (0–61.43 months).
Visual acuity in the worse eye on the date of presentation
ranged between 1.54 and 0 log minimum angle of resolution
(MAR) (mean, 0.34 logMAR, Table 1). On last examina-
tion, visual acuity was between 0.4 and 0 logMAR (mean,
0.09 logMAR). Taken together, visual acuity improved in 9
of 18 patients from a mean of 0.64 logMAR to a mean of
0.17 logMAR in the worse eye. In nine patients, it remained
stable (mean, 0.03 logMAR). Near visual acuity was taken
in nine patients (50 %) at follow-up exam and ranged from
0.52 logMAR to 0 logMAR in the worse eye (mean, 0.11
logMAR). All 9 patients (50 %) who were assessed by the
Amsler test complained about metamorphopsias in the grid.
Fig. 1 Funduscopically creamy
white lesions can be seen
(a: fundus photography,
b: autofluorescene image)
which later can leave
chorioretinal scars. In the
fluorescein angiogram, the
lesions typically show early
hypofluorescence and late
hyperfluorescence (c, d)
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Of the 13 patients who underwent a follow-up examination,
all showed funduscopically small pigmented scars with no
activity. The scars could be well visualized using FAF. The
results of the fluorescein angiogram (17 patients; one patient
refused the procedure) were all in agreement with the diag-
nosis of APMPPE. The angiograms that were taken in the
acute phase all showed the typical staining pattern of early
hypofluorescence and late hyperfluorescence. Angiograms
that were taken later in the course of the disease showed
inactive staining of scars. All 11 multifocal ERGs that were
performed (ten at follow-up and one at a relatively acute
phase) were pathological: mainly reduced sum responses
and or reduced responses of the foveal and parafoveal
regions. Fifteen out of 18 patients received a 30° static
perimetry. These patients could be divided into three groups:
group 1 (three patients) who only had perimetry at one of
their first visits, group 2 (six patients) who had perimetry
only at follow-up and group 3 (six patients) who had peri-
metry at one of their first visits as well as at follow-up. To be
able to objectively compare the results of the perimetry, the
mean defect (MD) values in decibels were analysed. In
group 1, the mean MD was 1.1 dB (range, −0.6 to
4.1 dB). In group 2, the mean MD was 0.03 dB (range,
−1.6 to 1.3 dB). The exact numbers are displayed in Table 1.
In group 3, the mean MD was 4.14 dB (range, −1.2 to
10.8 dB) initially and improved to a mean of 1.77 dB (range,






























1 M 24 1 0/0 0/0 No nd No f/u nd No f/u nd
2 F 24 4 0/1.54 0/0.3 Yes nd No f/u nd No f/u 1.9/4.1 1
3 F 35 42.57 0/0.1 0/0 Yes 0/0.1 Scars R>L
metas
nd 1.0/0.4 2
4 F 21 105 0/0 0/0 No nd Scars nd nd 1.0/1.3 2
5 M 31 55.14 0.1/0 0.1/0.1 No nd Scars nd Pathol −1.6/–1.3 2
6 F 28 149.14 0/0.1 0/0 Yes nd Scars nd Pathol 7.5/10.8→
3.0/3.4 3
7 F 17 82.57 0/0 0/0 No nd Scars nd Pathol 0.7/0.8 2




9 F 38 1.57 0.2/0 0.2/0 No nd No f/u nd No f/u nd




11 F 18 250 0.1/0 0/0 Yes 0/0 Scars R/L
metas
Pathol −0.7/–0.8 2
12 M 34 1.57 0.3/0.6 0.2/0.3 Yes nd No f/u nd No f/u nd




14 M 17 27.43 0/0.7 0/0.3 Yes nd No f/u nd No f/u −0.4/1.4 1
15 M 28 59 0/0 0/0 No 0/0 Scars R metas Pathol 0.7/–0.7→
0.7/–0.4 3
















Italicized numbers after the MD values represent the patient group as described in the text
DOP date of presentation, nd not done, f/u follow-up, metas metamorphopsias, pathol pathological, MD mean defect
a mfERG was performed only 1 week after first presentation
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−1.8 to 7.6 dB), indicating that the visual fields improve
after the acute phase of the disease. As can be seen in
Table 1, all patients but one (patient 8) had an improvement
of the visual fields at follow-up compared to the initial
exam. One explanation why patient 8 did not improve is
that he was our oldest patient and that his general health
status at the day of the follow-up exam was poor. Especially
in group 3, the MD shows a very broad range confirming
that the disease can have varying extents. When looking at
the visual fields of all patients that had a follow-up perime-
try (i.e. groups 2 and 3), we felt that 6 out of 12 patients had
remaining mostly small visual field defects. All but one
patient had no more relapses of ocular disease at the end
of the first treatment period. The one patient who relapsed
had increasing visual field defects that improved after in-
creasing the corticosteroid dosage.
Fifteen patients (83 %) were treated with systemic corti-
costeroids. The initial dosage ranged from 50 to 250 mg
(mean, 106 mg) and was determined by the physician on
duty who had the first contact with the patient. As far as it
can be said retrospectively, the initial dosage was chosen
independently of the presence of neurological symptoms.
The treatment period ranged between 3 weeks and several
months, whereas 47 % of the treated patients received
treatment for approximately 1 month. The speed and amount
of steroid taper were adjusted to the patient's individual
visual and physical recovery (e.g. headaches resolved).
The one relapsing patient received additional immunosup-
pressive medication for 38 weeks which then could be
stopped without further relapse. The stroke patient received
additional cyclophosphamide for CNS vasculitis.
Eleven patients (61 %) had neurologic symptoms of
varying severity (Table 2). In most patients, the neurological
symptoms started at the same time or close to the beginning
of the ocular symptoms. However, the most severe neuro-
logical complication we witnessed—cerebral stroke with
hemiparesis and aphasia—took place 2 months after the first
symptoms (headaches and visual complaints). This 58-year-
old patient (Table 2, patient 8) received 200 mg prednisone
at presentation which was slowly tapered. He was on 80 mg
prednisone per day when the stroke took place. Six days
earlier, he had still complained about headaches. The MRI
showed multiple areas of infarction consistent with vasculi-
tis. Embolising cardiac disease, stenosis of cerebral vessels
and paraneoplastic disease were ruled out as underlying
causes of the stroke. A biopsy of the dura mater revealed
lymphocytic infiltrates as a morphological sign of vasculitis.
The most common neurological symptom was headache
occurring in nine (50 %) patients (Table 2). Three patients
had sensory symptoms like hyp- or paraesthesias, one pa-
tient experienced psychosis and one patient complained
about vertigo. Overall, 12 out of the 14 patients that had a
brain MRI did not show signs of vasculitis. Four patients
showed abnormalities in the MRI (Table 2, patients 8, 10, 13
and 16). The findings in patients 10 (gliotic changes) and 16
(pineal cyst) were considered insignificant. In patient 16, a
CSF examination was performed due to abnormal TCD
results, but CSF results were normal. Patient 8, the stroke
patient, presented with bilateral contrast medium enhance-
ment of optic nerve sheaths and nodular changes in the
orbits, possibly granulomatous before he developed the
stroke. CSF examination was normal at this point in time.
For patient 13, who had unspecific bilateral signal intensi-
ties in the subcortical frontal area, possibly gliosis, a CSF
examination was recommended but was declined by the
patient.
In total, CSF examination was performed in six patients.
Four had normal results. Two patients with headaches and
normal MRI showed pleocytosis and/or oligoclonal bands.
TCD sonography showed abnormalities in 6 of 14 tested
patients. Interestingly, the MRI results, TCD and the CSF
analysis did not necessarily correlate with each other. Electro-
physiologic exams were not helpful in indicating CNS affec-
tion. More detailed results of neurological manifestations and
technical abnormalities will be published separately.
Discussion
APMPPE is a rare disease, and therefore, there are not many
systematic reports in the literature. So far, mainly case
reports but also some studies with case series have been
published. Most studies were done retrospectively as this is
often the case with rare diseases. The published studies are
difficult to compare and to summarize because emphasis
was put on different aspects of the disease. In our study,
we focused on two aspects of the disease: the visual, overall
outcome and CNS involvement. Seventy-two percent of our
patients were examined in a prospective follow-up exam.
Visual loss is the most obvious symptom for the patient
and brings the patient to the ophthalmologist. Visual recov-
ery is the most important aim for the patient and the oph-
thalmologist. In our group of patients, the mean finally
measured visual acuity was 0.09 logMAR. Half of the
patients had an improvement of visual acuity in the worse
eye (mean final visual acuity, 0.17 logMAR) compared to
the date of presentation (mean, 0.64 logMar). The other half
remained stable (mean first and final visual acuity, 0.03
logMar) but had an overall better initial visual acuity. That
visual recovery may be incomplete in some patients is in
agreement with Fiore et al. [3]. They found in an extensive
literature review as well as in a group of their own patients
that APMPPE has a relatively benign visual prognosis, but
compared to other white dot syndromes, there are patients
with incomplete visual recovery. Fiore states, in agreement
with other relatively recent reports [4, 5], that nearly 50 % of
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the eyes reached an incomplete recovery in visual acuity
(≤0.1 logMAR) and that approximately 25 % of the eyes
have a more limited visual recovery (≤0.3 logMAR). In
contrast, some older publications describe a good visual
prognosis [6-9]. A long-term study (average follow-up 5
years) conducted by Gass [10] revealed that only 2 out of
59 eyes achieved a visual acuity less than 0.18 logMAR.
Our study also revealed a good outcome looking at visual
acuities, but all patients showed scarring of the posterior
pole that was mirrored by persistent visual field defects in
the central 30° in two thirds of the patients examined. Still,
good reading abilities were shown in those patients where
near distance visual acuities were obtained, albeit with
metamorphopsias in all of these patients. As APMPPE is a
disease that afflicts relatively young patients, we need to
find out how we can prevent the scarring and thus improve
outcome.
Neurological involvement may not be as obvious as the
reduction of visual acuity. We observed mainly headaches
which occurred in half of the patients. Of patients with head-
aches, only four described flu-like symptoms. Headaches can
represent a neurological symptom on its own or can be part of
the flu-like symptoms which patients sometimes report. The
most severe neurological complication we witnessed was
stroke caused by histologically proven cerebral vasculitis.
In a Medline search, we found 31 APMPPE patients with
neurological manifestations [2, 3, 11–18]. Cerebral stroke
occurred in 16 cases. Our case series adds another 11
patients with neurological symptoms and 1 with cerebral
stroke. Several authors describe angiography findings that
are in line with cerebral vasculitis (e.g. focal stenosis,
lumen fluctuation), but in only two cases, vasculitis was
histologically proven [19–21].
Other neurological manifestations that are described in
the literature are vertigo, dysarthria, ataxia, tremor, para-
esthesias, migraine and cavernous sinus thrombosis [14].
Of note in our study was the fact that MRI results did not
necessarily correlate with CSF abnormalities. Patients 5 and
6 (Table 2) had normal MRIs but abnormal CSF findings.
Vice versa, our stroke patient (patient 8) displayed patho-
logical findings at cranial MRI, yet had a normal CSF.
Pathological CSF results in APMPPE patients with or
Table 2 Neurological symptoms
Patient
no.
Sex Age at DOP
(years)
Neurological symptoms MRI Lumbar puncture
1 M 24 Headaches, psychosis Normal nd
2 F 24 Headaches Normal nd
3 F 35 Headaches nd nd
4 F 21 Headaches Normal nd
5 M 31 Headaches Normal Abnormal
6 F 28 Headaches, myalgia, vertigo,
paraesthesias both extremities
Normal Abnormal
7 F 17 Headaches Normal Normal
8 M 58 Initially: headaches; later: stroke,
hemiparesis, aphasia
Initially: contrast medium enhancement of
optic nerve sheaths and nodular changes in
the orbits, possibly granulomatous bilaterally;




9 F 38 None nd nd
10 M 32 Hypaesthesia, right thumb Single small unspecific gliotic changes, left
hemisphere
nd
11 F 18 None Normal nd
12 M 34 None nd nd
13 F 16 None Unspecific bilateral signal intensities
in the subcortical frontal area, possibly gliosis
Recommended
14 M 17 None nd nd
15 M 28 Paraesthesias, right foot;
hypaesthesia, right side of body
Normal Normal
16 M 23 None Consistent with right temporal small cavernoma
pineal cyst
Normal
17 F 50 None Normal nd
18 M 21 Headaches Normal nd
DOP date of presentation, nd not done, MRI magnetic resonance imaging
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without major neurological complications have been de-
scribed [22–24].
We did not detect a clear correlation between ophthalmo-
logic impairment and the rather heterogeneous neurologic
manifestations. For example, patient 8, the patient with the
worst neurological complication, also had one of the worst
visual acuities and MD values. In this case, there is a
positive correlation. On the other hand, patient 5 who had
headaches and changes in the CSF had a very good visual
acuity (V/A) and visual field. Ophthalmologic findings in
patient 6 illustrate that even visual acuity and visual field do
not necessarily correlate. This patient who complained of
different neurological symptoms and had changes in the
CSF had a very good V/A, but pronounced field defects.
Depending on the localisation of the retinal lesions, espe-
cially the involvement of the fovea, patients might have a
good V/A, but a bad visual field. To judge if a patient is in
danger of neurological complications, the severity of the
visual loss and field defects are not a reliable marker. We
think that it is more helpful to explicitly ask the patient
about neurological symptoms and in the case of doubt lean
towards lumbar puncture to rule out CNS involvement.
Other non-invasive neurological examinations may be su-
perior (manuscript in preparation).
We conclude that neurological signs and symptoms, espe-
cially headaches, are frequent in APMPPE and should be
taken seriously. Adequate investigations including MRI and
CSF examination should be initiated in these patients. Our
patients with persisting neurological symptoms and suspect
MRI or CSF results were monitored closely by us and the
neurologists. It may be discussed that CSF investigations
should be performed even in an asymptomatic, MRI negative
APMPPE patient as ocular symptomsmay precede neurologic
symptoms or ophthalmic treatment may masquerade neuro-
logic manifestation. If neurological symptoms persist despite
treatment, it might even be advisory to repeat MRI or CSF as
we learn from our stroke patient where the initial MRI and
CSF were not able to identify vasculitis. Immunomodulatory
treatment might be of prognostic relevance, but no prospective
studies have been performed. It is unlikely that they will ever
be performed, as the disease is so rare. In our cohort, only
three patients did not receive treatment, and their outcome did
not differ from the rest of the group. At the same time, 80 mg
of prednisone did not prevent the stroke in the described
patient. Some authors question the need to treat APMPPE
patients arguing that therapy does not alter the natural course
of the disease [10, 18, 25]. Fiore et al. [3] conclude that the use
of oral corticosteroids remains unclear and that more defini-
tive data are required. Several authors agree that rapid treat-
ment is indicated when CNS complications accompany
APMPPE [2, 22].
We think that the very high corticosteroid starting dos-
ages (>1 mg/kg body weight) which were chosen in some of
the patients by the physicians on duty for the ophthalmo-
logic aspect alone were too high. But, if one considers the
assumed pathogenesis, an immune hyperreactivity after a
viral infection, it feels like a logical consequence to use oral
corticosteroids to soften that immune response. At the same
time, it may prolong ongoing viral activity.
In conclusion, we have shown in this case series of 18
patients that visual prognosis is good in patients with
APMPPE, but visual field defects may remain, significantly
reducing quality of vision in the majority of the patients.
Neurological complications may be serious and have to be
considered at the time of diagnosis of APMPPE. Concluding
from our results, all patients with the diagnosis APMPPE
should receive a clinical neurological examination, cerebral
MRI and TCD with subsequent lumbar puncture if any of
these three shows abnormalities. Treatment with oral cortico-
steroids should be discussed with the neurologists and with the
patient as a benefit over natural history cannot be guaranteed.
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